Webinar, topic: "Biosimilars and the BPCI Act: Where Are We Now and Where Are We Going?"‎

Kenneth Burchfiel and Dr. William J. Simmons featured as panelists on an upcoming American ‎Bar Association webinar. (CLE credit available)

Kenneth Burchfiel and Dr. William J. Simmons are members of the biosimilar practice group at ‎Sughrue Mion, PLLC which addresses the complex patent issues associated with the ‎BPCI. Sughrue has been at the forefront of this law and provides strategic counseling ‎regarding all aspects of the intellectual property issues raised by the Approval Pathway for ‎Biosimilar Biological Products. The intricate US Pathway sets forth the law for the production, ‎use and sale of follow-on biologic therapeutics in the U.S., including provisions designed for ‎determining the outcome of intellectual property disputes. During this webinar, Kenneth ‎Burchfiel and Dr. William J. Simmons will discuss some of the critical patent issues involved in ‎exploitation of the BPCI, in view of the America Invents Act (AIA). ‎